EyePoint Pharmaceuticals, Inc.
EYPT
$13.98
$0.0950.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -59.43M | -45.20M | -41.40M | -29.36M | -30.83M |
| Total Depreciation and Amortization | 538.00K | 497.00K | 467.00K | 408.00K | 362.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.59M | 6.09M | 6.18M | 5.57M | 7.00M |
| Change in Net Operating Assets | -9.29M | -14.51M | -1.10M | -15.65M | 3.28M |
| Cash from Operations | -62.59M | -53.12M | -35.85M | -39.03M | -20.18M |
| Capital Expenditure | -1.22M | -276.00K | -384.00K | -1.57M | -900.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 49.56M | 39.80M | -95.58M | 17.77M | -159.50M |
| Cash from Investing | 48.34M | 39.53M | -95.96M | 16.20M | -160.40M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -16.00K | -35.00K | -32.00K | -73.00K | -- |
| Issuance of Common Stock | 273.00K | 593.00K | 152.08M | 12.04M | 625.00K |
| Repurchase of Common Stock | -19.00K | -1.22M | 0.00 | -78.00K | -78.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -291.00K | -365.00K | 0.00 | -218.00K |
| Cash from Financing | 238.00K | -951.00K | 151.69M | 11.89M | 329.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.02M | -14.55M | 19.87M | -10.94M | -180.24M |